Legend Biotech Corp (LEGN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Legend Biotech Corp stock (LEGN) is currently trading at $17.60. Legend Biotech Corp PS ratio (Price-to-Sales) is 3.07. Analyst consensus price target for LEGN is $58.09. WallStSmart rates LEGN as Sell.
- LEGN PE ratio analysis and historical PE chart
- LEGN PS ratio (Price-to-Sales) history and trend
- LEGN intrinsic value — DCF, Graham Number, EPV models
- LEGN stock price prediction 2025 2026 2027 2028 2029 2030
- LEGN fair value vs current price
- LEGN insider transactions and insider buying
- Is LEGN undervalued or overvalued?
- Legend Biotech Corp financial analysis — revenue, earnings, cash flow
- LEGN Piotroski F-Score and Altman Z-Score
- LEGN analyst price target and Smart Rating
Legend Biotech Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Legend Biotech Corp (LEGN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Legend Biotech Corp (LEGN) Key Strengths (3)
Revenue surging 64.20% year-over-year
50.52% held by institutions, strong professional interest
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Legend Biotech Corp (LEGN) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Premium pricing at 3.2x book value
Revenue is fairly priced at 3.07x sales
Supporting Valuation Data
Legend Biotech Corp (LEGN) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 8.3/10) while 5 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 64.20%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (3.07), Price/Book (3.21) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -29.10%, Operating Margin at -6.72%, Profit Margin at -28.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -29.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 64.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LEGN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LEGN's Price-to-Sales ratio of 3.07x sits near its historical average of 3.47x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 21% below its historical high of 3.89x set in Mar 2026, and 0% above its historical low of 3.07x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Legend Biotech Corp (LEGN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Legend Biotech Corp is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 1.0B with 64% growth year-over-year. The company is currently unprofitable, posting a -28.8% profit margin.
Key Findings
Revenue growing at 64% YoY, reaching 1.0B. This pace significantly outperforms most BIOTECHNOLOGY peers.
The company is unprofitable with a -28.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -127M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Legend Biotech Corp maintain 64%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Legend Biotech Corp.
Bottom Line
Legend Biotech Corp is a high-conviction growth story with revenue accelerating at 64% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -28.8% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Legend Biotech Corp(LEGN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.